VIRAX BIOLABS GROUP LTD SHS NEW - Stock (VRAX)

CUSIP: G9495L109

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Stock
Total 13F shares
184,903
Share change
+126,530
Total reported value
$132,616
Price per share
$0.72
Number of holders
7
Value change
-$21,287
Number of buys
6
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP G9495L109?
CUSIP G9495L109 identifies VRAX - VIRAX BIOLABS GROUP LTD SHS NEW - Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of VIRAX BIOLABS GROUP LTD SHS NEW - Stock (VRAX) as of Q4 2022

As of 31 Dec 2022, VIRAX BIOLABS GROUP LTD SHS NEW - Stock (VRAX) was held by 7 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 184,903 shares. The largest 7 holders included Legal & General Group Plc, Virtu Financial LLC, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, UBS Group AG, MORGAN STANLEY, and Riggs Asset Managment Co. Inc.. This page lists 7 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.